Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis
article
OA: closed
CC0
⤵ 79 in-corpus citations
AI-generated summary
Dienogest demonstrated non-inferior efficacy to leuprolide acetate for endometriosis pain relief and symptom improvement, with superior quality-of-life outcomes and a favorable safety profile.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To analyze the secondary efficacy and safety outcomes from a recent trial comparing dienogest (DNG) with leuprolide acetate (LA) in women with endometriosis. METHODS: A 24-week, open-label, randomized, multicenter study of DNG versus LA in women with endometriosis-related pain was assessed for outcomes such as responder rates (using predefined thresholds of pain relief), changes in single symptoms/signs and sum scores from the Biberoglu and Behrman (B&B) scale, clinical laboratory parameters, and measures of quality of life. RESULTS: Dienogest was non-inferior to LA for treatment response using all predefined thresholds of pain relief and provided equivalent improvements in B&B symptoms and signs. No clinically relevant changes in laboratory parameters were observed during DNG treatment, whereas estrogen levels decreased in the LA group. Compared with LA, DNG was associated with pronounced improvements in specific quality-of-life measures. CONCLUSION: The analyses provide supportive evidence that the efficacy of DNG is equivalent to that of LA for treating endometriosis symptoms, with specific quality-of-life benefits and a favorable safety profile.
My notes (saved in your browser only)
Outcome instruments
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (24)
- A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis via openalex
- Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials via openalex
- Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex
- Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
- Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness via openalex
- Endometriosis: epidemiology and aetiological factors via openalex
- Evaluation of Quality of Life and Sexual Satisfaction in Women Suffering from Chronic Pelvic Pain With or Without Endometriosis via openalex
- Hormone treatment of endometriosis: The estrogenthreshold hypothesis via openalex
- Medical management of endometriosis: a systematic review. via openalex
- Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women via openalex
- PIH28 VALIDATION OF THE SF—36 IN PATIENTS WITH ENDOMETRIOSIS via openalex
- Progestogens for endometriosis: forward to the past via openalex
- Quantification of the impact of endometriosis symptoms on health-related quality of life and work productivity via openalex
- Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex
- The pharmacological profile of dienogest via openalex
- Use of the SF-36 questionnaire to predict quality-of-life improvement after laparoscopic colorectal resection for endometriosis via openalex
- Validation of the SF-36 in patients with endometriosis via openalex
- W4233775049 via openalex
- W2015986868 via openalex
- W2045458073 via openalex
- W2079044470 via openalex
- W2097719036 via openalex
- W2101417341 via openalex
Cited by (50)
- THERAPEUTIC OPTIONS IN ENDOMETRIOSIS: A COMPARATIVE LITERATURE REVIEW OF INTRAUTERINE DEVICE THERAPY, SURGICAL TREATMENT, RELUGOLIX COMBINATION THERAPY, AND DIENOGEST 2026
- Fertilizing role of leuprolide acetate in assisted human reproduction among infertile patients with endometriosis 2026
- Hormonal Treatment of Endometriosis: A Narrative Review 2025
- The effects of melatonin on endometriosis-associated pain and regression of endometrioma; a triple blind randomized controlled trial 2025
- Progestagens for pain symptoms associated with endometriosis 2025
- A systematic literature review on patient-reported outcome domains and measures in nonsurgical efficacy trials related to chronic pain associated with endometriosis: an urgent call to action 2024
- Superficial Peritoneal Endometriosis Vaporization Using a CO2 Laser: A Long-Term Single-Center Experience 2024
- Dienogest versus gonadotropin-releasing hormone analogues for the clinical treatment of endometriosis: an updated meta-analysis 2024
- Superficial Peritoneal Endometriosis Vaporization Using a CO2 Laser: a long-term single-center experience. 2024
- Safety and efficacy of pharmacotherapies for pelvic inflammatory disease and endometriosis 2024
- Dienogest in conjunction with GnRH-a for postoperative management of endometriosis 2024
- Endometriose 2024
- A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment 2023
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosis 2023
- Medikamentöse Therapie der Endometriose – ein Update 2023
- GnRH Agonists and Antagonists in Endometriosis and Adenomyosis Therapy 2022
- Clinical Diagnosis and Early Medical Management for Endometriosis: Consensus from Asian Expert Group 2022
- Hormonal Therapy in Endometriosis and Adenomyosis: Progestins 2022
- Medikamentöse Therapie der Endometriose – ein Update 2022
- The rarest forms of endometriosis 2022
- The ENDOPAIN 4D Questionnaire: A New Validated Tool for Assessing Pain in Endometriosis 2021
- Advances in the medical treatment of adolescent endometriosis 2021
- Observational Study for Adverse Effects and Discontinuation with Long-Term Post-Operative Hormonal Treatment for Endometriosis in Real-World Practice 2021
- Short-term Efficacy of Dienogest in Improving Pain in Patients with Endometriosis: A Single-center Experience 2021
- Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial 2021
- Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial 2021
- When and how should peritoneal endometriosis be operated on in order to improve fertility rates and symptoms? The experience and outcomes of nearly 100 cases 2021
- The effectiveness of therapy for endometriosis-associated pelvic pain resistant to surgical treatment 2021
- Risk factors for non‐response and discontinuation of Dienogest in endometriosis patients: A cohort study 2020
- Medical Management of Endometriosis in Adolescents 2020
- Dysmenorrhea, Endometriosis and Chronic Pelvic Pain in Adolescents 2020
- Medical therapy options for endometriosis related pain, which is better? A systematic review and network meta-analysis of randomized controlled trials 2020
- Is Scientific Medical Literature Related to Endometriosis Treatment Evidence-Based? A Systematic Review on Methodological Quality of Randomized Clinical Trials 2019
- Comparison of long-term use of combined oral contraceptive after gonadotropin-releasing hormone agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery 2019
- Systematic review of quality of life measures in patients with endometriosis 2019
- Effect of Dienogest and the GnRH-a in Endometriosis: A Meta-Analysis 2018
- Reviewing the role of progesterone therapy in endometriosis 2018
- Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice 2018
- Dienogest therapy during the early stages of recurrence of endometrioma might be an alternative therapeutic option to avoid repeat surgeries 2018
- Tratamientos farmacológicos de la endometriosis (a excepción de la adenomiosis) 2018
- Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma 2017
- Medical Therapies for Endometriosis Differentially Inhibit Stem Cell Recruitment 2017
- Dienogest Therapy as a Treatment for Catamenial Pneumothorax: Case Report and Review of Hormonal Options 2017
- Progestins in the Medical Management of Endometriosis 2017
- Traitement médical de l’endométriose : prise en charge de la douleur et de l’évolution des lésions par traitement hormonal et perspectives thérapeutiques 2017
- The Use of Resveratrol as an Adjuvant Treatment of Pain in Endometriosis: A Randomized Clinical Trial 2017
- Dienogest versus gonadotropin-releasing hormone analogue for the clinical treatment of endometriosis: a systematic review and meta-analysis 2017
- Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study 2017
- Reevaluating response and failure of medical treatment of endometriosis: a systematic review 2017
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:16:17.081435+00:00
License: CC0
· commercial use OK